Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD1 | P11586 | 4/20 | 0.39 |
| ▸ | MTHFD2 | P13995 | 4/20 | 0.39 |
| ▸ | ERN1 | O75460 | 2/20 | 0.32 |
| ▸ | WDR5 | P61964 | 5/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21354118 | 0.99 | MTHFD1 (0.38) | MTHFD1MTHFD2ERN1WDR5ADRA2A | |
| SCHEMBL20208615 | 0.86 | MTHFD2 (0.36) | MTHFD1MTHFD2ERN1 | |
| SCHEMBL31535176 | 0.85 | MTHFD1 (0.30) | MTHFD1MTHFD2 | |
| SCHEMBL31535444 | 0.85 | MTHFD1 (0.30) | MTHFD1MTHFD2 | |
| SCHEMBL20209028 | 0.83 | MTHFD2 (0.51) | MTHFD1MTHFD2ERN1 | |
| Hydrochloric Acid SCHEMBL21354111 | 0.82 | MTHFD2 (0.51) | MTHFD1MTHFD2ERN1 | |
| SCHEMBL31535487 | 0.81 | ERN1 (0.32) | ERN1 | |
| SCHEMBL21354119 | 0.80 | MTHFD2 (0.51) | MTHFD1MTHFD2ERN1WDR5 | |
| SCHEMBL31535274 | 0.77 | MTHFD1 (0.33) | MTHFD1MTHFD2 | |
| SCHEMBL31535257 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3546463-B1 | SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON | DAIICHI SANKYO CO LTD (JP) | 2022-12-07 | — | — | EP | disclosed |
| US-10774087-B2 | Sulfonamide derivative having coumarin skeleton | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-09-15 | — | — | US | disclosed |
| EP-3546463-A1 | SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON | Daiichi Sankyo Co., Ltd. (JP) | 2019-10-02 | — | — | EP | disclosed |
| US-20190284198-A1 | SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
| WO-2018097162-A1 | SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON | 第一三共株式会社 | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284198-A1 | SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON | MTHFD1, MTHFD2, DHFR | MTHFD1 1/4885MTHFD2 2/4885ERN1 2490/4885 |
| US-10774087-B2 | Sulfonamide derivative having coumarin skeleton | MTHFD1, MTHFD2, DHFR | MTHFD1 1/4885MTHFD2 2/4885ERN1 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.